ライフサイエンスコーパス: preeclampsia

1 2.5 for gestational hypertension and 2.4 for preeclampsia).

2 ular risk factors in women with a history of preeclampsia.

3 f DLX5 might help explain certain aspects of preeclampsia.

4 printed status and no prior association with preeclampsia.

5 g disturbed imprinting, gene expression, and preeclampsia.

6 during pregnancy reduces the risk of preterm preeclampsia.

7 ples from healthy controls and patients with preeclampsia.

8 nary soluble nephrin levels (nephrinuria) in preeclampsia.

9 00 cohort, 5.6% (n = 23) were diagnosed with preeclampsia.

10 Maternal asthma increased the risk of preeclampsia.

11 n (sFlt-1) is implicated in the pathology of preeclampsia.

12 cluding 745 women with GH and 815 women with preeclampsia.

13 tein, precede clinical signs and symptoms of preeclampsia.

14 were the most consistent findings in GH and preeclampsia.

15 ed with severe gestational diseases, such as preeclampsia.

16 he preclinical and clinical phases of GH and preeclampsia.

17 l outcomes in women with PPCM complicated by preeclampsia.

18 elieved to mediate the signs and symptoms of preeclampsia.

19 egnancy (10-18 weeks), on the development of preeclampsia.

20 epidemiological association between PFOA and preeclampsia.

21 tabolite concentrations during gestation and preeclampsia.

22 to 18 weeks in 47 participants who developed preeclampsia.

23 he development of chronic hypertension after preeclampsia.

24 ir reported epidemiological association with preeclampsia.

25 with low serum vitamin D levels who develop preeclampsia.

26 lar weight 16 kDa) have been associated with preeclampsia.

27 ation in placental macrophages is present in preeclampsia.

28 licated by gestational hypertension (GH) and preeclampsia.

29 une response in women who went on to develop preeclampsia.

30 ts and harms of treatment of screen-detected preeclampsia.

31 egnancy were associated with a lower risk of preeclampsia.

32 amin D supplementation for the prevention of preeclampsia.

33 nificantly associated with increased risk of preeclampsia.

34 n pregnancy was proposed as a risk factor of preeclampsia.

35 available for 816, with 67 (8.2%) developing preeclampsia.

36 d evidence associating APOL1 expression with preeclampsia.

37 hage-trophoblast interaction, is involved in preeclampsia.

38 to predict biological processes affected in preeclampsia.

39 to study the association of the variant with preeclampsia.

40 olites measured during pregnancy and risk of preeclampsia.

41 d obesity, two conditions that predispose to preeclampsia.

42 ly altered in the umbilical veins of GDM and preeclampsia.

43 verse maternal and fetal outcomes, including preeclampsia.

44 3.7% (n = 62,728) were born to mothers with preeclampsia.

45 smoking, gestational diabetes mellitus, and preeclampsia.

46 al infarction, stroke, cerebral malaria, and preeclampsia.

47 half met blood pressure criteria for severe preeclampsia.

48 evalence in those exposed and not exposed to preeclampsia.

49 iated with a slight reduction in the risk of preeclampsia.

50 pregnancy-related medical condition such as preeclampsia.

51 profile similar to those found in women with preeclampsia.

52 history of spontaneous abortion and risk of preeclampsia.

53 roup of women with subclinical or unresolved preeclampsia.

54 tal diagnosis of gestational hypertension or preeclampsia.

55 onships between maternal genotype and severe preeclampsia.

56 turity, because prematurity is an outcome of preeclampsia.

57 organs, contributing to the pathogenesis of preeclampsia.

58 whether disturbed imprinting contributes to preeclampsia.

59 Seventeen of 39 women (44%) with PPCM had preeclampsia.

60 atients with PPCM that is not complicated by preeclampsia.

61 idence, that imprinted genes are involved in preeclampsia.

62 rce (USPSTF) recommendation on screening for preeclampsia.

63 ular disease, stroke, and stroke death after preeclampsia.

64 million women including >258 000 women with preeclampsia.

65 tension and the pregnancy related condition, preeclampsia.

66 sproportionally affected by risk factors for preeclampsia.

67 ophysiology and clinical unpredictability of preeclampsia.

68 vailable in 10 survivors with and 16 without preeclampsia.

69 in some congenital heart defects and preterm preeclampsia.

70 ibutable risk of gestational hypertension or preeclampsia (11% versus 5% incidence in one study).

71 women (20-38 years of age) with very preterm preeclampsia (23-32 weeks of gestation, systolic BP >/=1

72 men also have case fatality rates related to preeclampsia 3 times higher than rates among white women

73 9 to 9.2], P<0.001), as was the incidence of preeclampsia (3.0% vs. 11.3%; odds ratio, 0.24; 95% conf

74 control (N = 408) groups in the incidence of preeclampsia (8.08% vs. 8.33%, respectively; relative ri

75 TMA is also a complication of preeclampsia, a disease characterized by excess producti

76 val, 11%-59%) in 3 women were complicated by preeclampsia, a frequency greater than US population est

77 ine and serum samples for early diagnosis of preeclampsia, a life-threatening hypertensive disorder t

78 centa actively produces transthyretin and in preeclampsia, a significant amount is extruded into the

79 L, mean +/- SD, p > 0.05, n = 8), however in preeclampsia, a significant proportion is vesicle-associ

80 nt, r-AKI associated with increased risk for preeclampsia (adjusted odds ratio [aOR], 5.9; 95% confid

81 e increase in DD risk associated with severe preeclampsia (adjusted odds ratio, 5.49; 95% CI, 2.06-14

82 d risk for other adverse outcomes, including preeclampsia (adjusted OR, 1.59 [95% CI, 1.54-1.63]), pr

83 Preeclampsia affects approximately 4% of pregnancies in

84 ; confidence interval, 1.3-13.1); late-onset preeclampsia (after week 34, hazard ratio, 2.0; confiden

85 IA) has been associated with a lower risk of preeclampsia among nulliparous women, but it remains unc

86 ate adjustment were applied to relate ROP to preeclampsia among the full cohort and in a subcohort of

87 1 and proteinuria in women with very preterm preeclampsia and appeared to prolong pregnancy without m

88 We studied associations between preeclampsia and asthma, allergy, and eczema in Copenhag

89 Preeclampsia and gestational diabetes mellitus (GDM) are

90 Preeclampsia and HELLP (hemolysis, elevated liver enzyme

91 duced pathways may be an avenue for treating preeclampsia and improving fetal outcomes.

92 ance understanding of the pathophysiology of preeclampsia and its subtypes.

93 as emerged as a common finding in women with preeclampsia and likely is a causative factor in this di

94 but were only modestly associated with term preeclampsia and not associated with gestational hyperte

95 Preeclampsia and placental insufficiency were self-repor

96 es affected by common complications, such as preeclampsia and preterm birth, display developmental ph

97 dies report conflicting associations between preeclampsia and retinopathy of prematurity (ROP).

98 We found disturbed placental imprinting in preeclampsia and revealed potential candidates, includin

99 To evaluate the association of maternal preeclampsia and risk of ROP among infants in an unrestr

100 epancies to clarify the relationship between preeclampsia and ROP.

101 ibution of endocrine-disrupting chemicals to preeclampsia and suggest a modifiable means to reduce th

102 rictor sensitivity that is characteristic of preeclampsia and suggest that targeting sFLT1-induced pa

103 ify the evidence on the relationship between preeclampsia and the future risk of cardiovascular disea

104 o confirm association between imprinting and preeclampsia and to predict biological processes affecte

105 ith APS given pravastatin after the onset of preeclampsia and/or IUGR compared with women in the cont

106 licated in the pathogenesis of hypertension, preeclampsia, and chronic kidney disease.

107 /J x DBA/2 has been recognized as a model of preeclampsia, and complement activation has been implica

108 reeclampsia, late preterm preeclampsia, term preeclampsia, and gestational hypertension.

109 man, such as recurrent spontaneous abortion, preeclampsia, and intrauterine growth restriction.

110 nation (c statistic >0.80) for prediction of preeclampsia, and positive predictive values of 4% in th

111 to placental insufficiency, hypertension, or preeclampsia; and small-for-gestational-age (SGA) neonat

112 e pregnancy and delivery outcomes, including preeclampsia (aRR 1.24; 95% CI, 1.07-1.43), infection (a

113 e as likely to have been exposed in utero to preeclampsia as controls with TD after adjustment for ma

114 the harms of screening for and treatment of preeclampsia as no greater than small.

115 There were 50 cases of preeclampsia as part of this study.

116 (RGS2) in the mother has been implicated in preeclampsia as well as in the development of chronic hy

117 the incidence of gestational diabetes and of preeclampsia, as well as the incidence of adverse neonat

118 Furthermore, renal injury in preeclampsia associated with an elevated urinary podocin

119 noncritical heart defects in offspring, and preeclampsia before 34 weeks was associated with critica

120 The primary outcome was delivery with preeclampsia before 37 weeks of gestation.

121 -onset preeclampsia, but are also markers of preeclampsia before clinical manifestation, and are asso

122 ng are most marked in severe and early-onset preeclampsia, but are also markers of preeclampsia befor

123 pregnant women before the clinical onset of preeclampsia, but its predictive value in women with sus

124 fferences in the associations between IA and preeclampsia by timing and method of IA were small, with

125 -gestation or preterm infant and early-onset preeclampsia (by week 34) significantly predicted premat

126 formed a nested case-control study of 12,650 preeclampsia cases and 50,600 matched control deliveries

127 tion on intragenic regions from both GDM and preeclampsia compared to healthy controls.

128 ver, women with r-AKI had increased rates of preeclampsia compared with controls (23% versus 4%; P<0.

129 significantly higher in pregnant women with preeclampsia compared with normotensive pregnant women (

130 y activated (P <0.05) in pregnant women with preeclampsia compared with normotensive pregnant women.

131 entas of women with periodontitis-associated preeclampsia compared with that in normotensive pregnant

132 PAR-gamma was downregulated in patients with preeclampsia compared with that of healthy normotensive

133 cluded in-hospital arrhythmias, eclampsia or preeclampsia, congestive heart failure (CHF), length of

134 in 697 controls from the Finnish Genetics of Preeclampsia Consortium (FINNPEC) cohort to study the as

135 Sensitivity analyses showed that preeclampsia continued to be associated with an increase

136 ys (range 0-14) in untreated contemporaneous preeclampsia controls (n=22).

137 ctivation in trophoblast cells of women with preeclampsia corroborates the translational relevance of

138 ngest in offspring from pregnancies in which preeclampsia developed during late gestation and offspri

139 al heart defects in infants of women who had preeclampsia during pregnancy is poorly understood, desp

140 egnancy, and complications during pregnancy (preeclampsia, eclampsia, hemorrhage, and hyperemesis).

141 e studies included pregnant women with GH or preeclampsia, evaluating left ventricular structure and

142 d in peripheral blood of women who developed preeclampsia (FDR <0.05 in the Vitamin D Antenatal Asthm

143 lacental complications of pregnancy, such as preeclampsia, fetal growth restriction, and stillbirth.

144 elopment of pregnancy complications, such as preeclampsia, fetal growth restriction, and stillbirth.

145 ciated phenotype that encompassed eclampsia, preeclampsia, fetal/neonatal deaths, and small litter si

146 ncentrations and assess the association with preeclampsia from 1990 through 2006 for the C8 Health Pr

147 ing, prenatal glucocorticoid administration, preeclampsia, gestational age at delivery, days in inten

148 Infants of women with preeclampsia had no increased prevalence of critical hea

149 Women with preeclampsia had smaller mean LV end-diastolic diameters

150 In time to event analysis, patients with preeclampsia had worse event-free survival during 1-year

151 on of environmental toxicants to the risk of preeclampsia has been sparse.

152 nd three individuals were considered to have preeclampsia/HELLP syndrome before the definitive diagno

153 ternal body mass index, higher maternal age, preeclampsia, higher socioeconomic position (SEP) and ma

154 iomyopathy (PPCM), but it is unknown whether preeclampsia impacts clinical or left ventricular (LV) f

155 ther evaluation of statins for prevention of preeclampsia in a large-scale randomized clinical trial.

156 abortion is associated with a lower risk of preeclampsia in a later pregnancy, focusing on the hypot

157 Similarly, preterm preeclampsia in a previous pregnancy, but not term preec

158 owever, the polymorphism was associated with preeclampsia in a subgroup of overweight women (body mas

159 contribute to poor outcomes associated with preeclampsia in African American women.

160 dels were used to calculate hazard ratios of preeclampsia in association with an interquartile range

161 Preeclampsia in combination with preexisting hypertensio

162 en with hypertensive disorders of pregnancy, preeclampsia in particular, have an increased risk of ca

163 The USPSTF recommends screening for preeclampsia in pregnant women with blood pressure measu

164 s a substantial net benefit of screening for preeclampsia in pregnant women.

165 y were also strongly associated with preterm preeclampsia in subsequent pregnancies (early preterm pr

166 e association between perfluorooctanoate and preeclampsia in the C8 Health Project population.

167 he occurrence of ROP was related to maternal preeclampsia in the full cohort and in a subcohort of P-

168 be predictive of the absence or presence of preeclampsia in the short term in women with singleton p

169 er had a negative predictive value (i.e., no preeclampsia in the subsequent week) of 99.3% (95% confi

170 be used to predict the short-term absence of preeclampsia in women in whom the syndrome is suspected

171 in D (25-hydroxyvitamin D [25OHD]) levels on preeclampsia incidence at trial entry and in the third t

172 d in weeks 10-18 of pregnancy did not reduce preeclampsia incidence in the intention-to-treat paradig

173 gnant women) and 25 were pregnant women with preeclampsia, including those with gestational hypertens

174 nearby variant, rs12050029, associated with preeclampsia independently of rs4769613.

175 centa plays a central role in development of preeclampsia, investigation into the contribution of env

176 Preeclampsia is a common and heterogeneous vascular synd

177 Preeclampsia is a common complication of pregnancy that

178 Preeclampsia is a complex and common human-specific preg

179 Preeclampsia is a complex disease of pregnancy with some

180 Preeclampsia is a devastating complication of pregnancy.

181 We first aimed to confirm that preeclampsia is a disease of the placenta by generating

182 Preeclampsia is a hypertensive disorder of pregnancy in

183 Preeclampsia is a leading cause of maternal death, espec

184 Preeclampsia is a pregnancy-specific disorder resulting

185 Preeclampsia is a risk factor for the development of per

186 Preeclampsia is a shared prenatal risk factor for asthma

187 Preterm preeclampsia is an important cause of maternal and perin

188 Preeclampsia is associated with a 4-fold increase in fut

189 PPCM with concomitant preeclampsia is associated with increased morbidity and

190 Subpopulation Considerations: Preeclampsia is more prevalent among African American wo

191 its predictive value in women with suspected preeclampsia is unclear.

192 further research on the role of vitamin D in preeclampsia is warranted.

193 ading to intrauterine growth restriction and preeclampsia, is the failure of invading extravillous tr

194 ory of induced abortion have a lower risk of preeclampsia, it is difficult to evaluate whether the ob

195 ends in a birth protects against subsequent preeclampsia, it is unclear whether a pregnancy ending i

196 to the similarities in pathophysiology among preeclampsia, IUGR, and atherosclerotic cardiovascular d

197 New criteria to diagnose preeclampsia, judicious reliance on measurement of ADAMT

198 ng congenital heart defects or early preterm preeclampsia, late preterm preeclampsia, term preeclamps

199 Many of the complications associated with preeclampsia lead to early induction of labor or cesarea

200 ptic serum is also aggregated and can induce preeclampsia-like symptoms in pregnant IL10(-/-) mice.

201 Levels of DLX5 correlated with classic preeclampsia markers.

202 Preeclampsia may trigger aberrant neurodevelopment throu

203 ension and angiotensin II sensitivity in the preeclampsia mouse model.

204 age, prepregnancy diabetes mellitus, preterm preeclampsia, multiple birth, and termination of pregnan

205 hose with intrauterine growth restriction or preeclampsia (N = 12).

206 ce among women being evaluated for suspected preeclampsia (n = 1888) had wide-ranging test accuracy (

207 maturely to untreated women with and without preeclampsia (n=22 per group), no adverse effects of aph

208 years of follow-up among women with moderate preeclampsia, n = 102 cardiomyopathy events; 14.6/100,00

209 n-years of follow-up among women with severe preeclampsia, n = 27 cardiomyopathy events; 15.6/100,000

210 emopexin, which were decreased in women with preeclampsia, negatively correlated with proteinuria, ur

211 Preterm preeclampsia occurred in 13 participants (1.6%) in the a

212 he increased aggregation of transthyretin in preeclampsia occurs at the post-transcriptional level an

213 y, especially pronounced after a duration of preeclampsia of 14 days or more.

214 Preeclampsia or eclampsia with onset before or after 34

215 ny vs no HDP, 1.54 (95% CI, 1.39-1.70) after preeclampsia or eclampsia, 1.51 (95% CI, 1.27-1.80) afte

216 ve disorder of pregnancy (severe or moderate preeclampsia or gestational hypertension) registered in

217 ampsia in a previous pregnancy, but not term preeclampsia or gestational hypertension, was associated

218 n and heparin, has not been shown to prevent preeclampsia or intrauterine growth restriction (IUGR).

219 ranes, or "placental," which was preceded by preeclampsia or intrauterine growth restriction.

220 l deaths (1 woman had used LMWH); 9 cases of preeclampsia or the hemolysis, elevated liver enzyme lev

221 me pregnancy and weakly associated with term preeclampsia (OR, 1.16; 95% CI, 1.06-1.27), but they wer

222 e interval [CI], 6.11-8.03) and late preterm preeclampsia (OR, 2.82; 95% CI, 2.38-3.34) in the same p

223 betes status, r-AKI remained associated with preeclampsia (OR, 4.7; 95% CI, 2.1 to 10.1) and adverse

224 were strongly associated with early preterm preeclampsia (OR, 7.00; 95% confidence interval [CI], 6.

225 gnancy (HDP) (gestational hypertension [GH], preeclampsia, or eclampsia) and 1.81 (95% CI, 1.44-2.27)

226 eclampsia: OR, 2.83; 95% CI, 2.11-3.79; term preeclampsia: OR, 0.98; 95% CI, 0.88-1.10; gestational h

227 a: OR, 2.37; 95% CI, 1.68-3.34; late preterm preeclampsia: OR, 2.04; 95% CI, 1.52-2.75) but were only

228 sia in subsequent pregnancies (early preterm preeclampsia: OR, 2.37; 95% CI, 1.68-3.34; late preterm

229 a: OR, 7.91; 95% CI, 6.06-10.3; late preterm preeclampsia: OR, 2.83; 95% CI, 2.11-3.79; term preeclam

230 defects in later pregnancies (early preterm preeclampsia: OR, 7.91; 95% CI, 6.06-10.3; late preterm

231 in 80% of survivors with versus 25% without preeclampsia (P=0.014).

232 of diagnosis (4/15 with versus 1/17 without preeclampsia; P=0.16).

233 at diagnosis (29.6 with versus 27.3 without preeclampsia; P=0.5).

234 GS2 might be involved in the pathogenesis of preeclampsia particularly in overweight women and contri

235 Preeclampsia, particularly severe disease, is associated

236 phosphorylation in placental tissue of human preeclampsia patients.

237 Preeclampsia (PE) and fetal growth restriction (FGR) are

238 sufficiency-associated complications such as preeclampsia (PE) and intrauterine growth restriction (I

239 Maternal symptoms of preeclampsia (PE) are primarily driven by excess anti-an

240 The pathogenesis of preeclampsia (PE) includes the release of placental fact

241 Preeclampsia (PE) is a dangerous and unpredictable pregn

242 Preeclampsia (PE) is a placenta-induced inflammatory dis

243 Preeclampsia (PE) is a pregnancy-specific syndrome, char

244 t invasion and differentiation can result in preeclampsia (PE), a hypertensive disorder of pregnancy

245 Preeclampsia (PE), a serious hypertensive disorder of pr

246 In preeclampsia (PE), cytotrophoblast (CTB) invasion of the

247 During the pregnancy associated syndrome preeclampsia (PE), there is increased release of placent

248 al death, cesarean delivery, length of stay, preeclampsia, preterm labor, and stillbirth.

249 supplementation had no effect on the risk of preeclampsia, reduced maternal serum vitamin D levels di

250 RATIONALE: Preeclampsia reflects an unusual increase in systemic in

251 evidence that urinary EVs are reflective of preeclampsia-related altered podocyte protein expression

252 The causes of preeclampsia remain unclear, but there is evidence for i

253 Preeclampsia represents a major cause of maternal mortal

254 r in vitro model might fill a vital niche in preeclampsia research.

255 se aspirin in women at high risk for preterm preeclampsia resulted in a lower incidence of this diagn

256 F found adequate evidence that screening for preeclampsia results in a substantial benefit for the mo

257 al serum vitamin D levels did correlate with preeclampsia risk.

258 story of miscarriage was not associated with preeclampsia risk.

259 ; 95% confidence interval [CI], 1.94-18.44), preeclampsia (RR, 2.43; 95% CI, 1.75-3.39), stillbirth (

260 tematically review the benefits and harms of preeclampsia screening and risk assessment for the US Pr

261 Evidence to estimate benefits and harms of preeclampsia screening and the test performance of diffe

262 ectiveness, benefits, and harms from routine preeclampsia screening during pregnancy.

263 udies directly compared the effectiveness of preeclampsia screening in a screened population vs an un

264 CI, 1.18-4.68); risk increased with greater preeclampsia severity (test for trend, P = .02).

265 analysis using loci bearing unique GDM- and preeclampsia-specific loss-of-5hmC indicated its impact

266 g neurodevelopmental function were masked to preeclampsia status.

267 pigenetic Birth Cohort and the Predictors of Preeclampsia Study.

268 or early preterm preeclampsia, late preterm preeclampsia, term preeclampsia, and gestational hyperte

269 defects was higher for infants of women with preeclampsia than those without it.

270 otential benefits and harms of screening for preeclampsia, the effectiveness of risk prediction tools

271 curacy of screening and diagnostic tests for preeclampsia, the potential benefits and harms of screen

272 In preeclampsia, the serum levels of transthyretin, a carri

273 Currently, delivery is the only cure for preeclampsia; therefore, effective prevention and treatm

274 mpared with infants of women with late-onset preeclampsia, those with early onset (<34 weeks) had gre

275 or pregnancy-related complication, including preeclampsia, thrombotic microangiopathy, heart failure,

276 regnancies who were at high risk for preterm preeclampsia to receive aspirin, at a dose of 150 mg per

277 Term preeclampsia (tPE), >/=37 weeks, is the most common form

278 cid for rapid and routine diagnosis of early preeclampsia using electrochemical-surface enhanced Rama

279 Preeclampsia was associated with an increased risk of de

280 Preeclampsia was associated with elevated total choleste

281 Preeclampsia was associated with increased risk of asthm

282 Preeclampsia was associated with increased risk of treat

283 No association between rs4606 and preeclampsia was detected in the analysis including all

284 for potential confounders demonstrated that preeclampsia was independently associated with an increa

285 Gestational hypertension or preeclampsia was more common among living kidney donors

286 Gestational hypertension or preeclampsia was more likely to be diagnosed in kidney d

287 In this population-based study, preeclampsia was significantly associated with noncritic

288 in women with singleton pregnancies in whom preeclampsia was suspected (24 weeks 0 days to 36 weeks

289 Children born to mothers with preeclampsia were analyzed regarding risk of asthma, all

290 Physicians diagnosing preeclampsia were masked to neurodevelopmental outcome,

291 owth factor, both biomarkers associated with preeclampsia, were measured on antepartum blood samples.

292 weeks gestation was associated with onset of preeclampsia, whereas significantly elevated hazard rati

293 Preeclampsia, which affects approximately 5% of pregnanc

294 Meta-analysis showed a higher risk of severe preeclampsia with coagulation factor V gene (proacceleri

295 ulty placentation manifests in the mother as preeclampsia with vascular damage, enhanced systemic inf

296 revalence is found among pregnant women with preeclampsia, with increased percentage of sites with BO

297 prior IA was associated with a lower risk of preeclampsia, with odds ratios of 0.9 (95% confidence in

298 low a derived cutoff) predict the absence of preeclampsia within 1 week after the first visit and whe

299 Flt-1:PlGF ratio above 38 for a diagnosis of preeclampsia within 4 weeks was 36.7% (95% CI, 28.4 to 4

300 s (above the cutoff) predict the presence of preeclampsia within 4 weeks.